Cadence Design Systems unveiled on Wednesday a new supercomputer based on chips from Nvidia that will speed up its software ...

This could give enterprises access to a 3D, AI-accelerated future without requiring investment in costly GPU-scale ...

So, here we are, launching our fourth edition of Fierce Biotech's layoff tracker. As always, if you know of a layoff occurring at a biotech, please reach out to the Fierce Biotech editorial team ...

Unlike Trump’s first term, the pharmaceutical industry is in far more peril than it has ever been in, and the biotech industry needs to ask itself an important question: Where does it fit in ...

Unity Biotechnology, a Bay Area company that once won high-profile backers and a $700 million valuation for its research into aging, is now laying off every one of its remaining employees.

The company said in a release last month about a human clinical trial that it is “a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last ...

Biotech stocks are in the eye of the storm as the world recovers from the global pandemic. Government institutions and professional traders are banking on biotech stocks to continually develop a ...

Pennsylvania-based Windtree Therapeutics is an unlikely new entrant in the city's multifamily scene, purchasing a 436-unit property in Houston as it attempts to diversify its holdings. The drug ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top ...

The numbers for first quarter 2025 biotech financings are in and they show a downturn in investments. A total of $6.5 billion was raised in the first quarter compared to $8.1 billion in the same ...

Eli Lilly has added another candidate to a growing pipeline of amyotrophic lateral sclerosis (ALS) therapies, tapping UK start-up Alchemab for an antibody currently being prepared for clinical ...